Long intergenic non-protein coding RNA 1117 (LINC01117)

**Long intergenic non-protein coding RNA 1117 (LINC01117)** is a long non-coding RNA belonging to the subclass of long intergenic non-coding RNAs, defined as RNA molecules longer than 200 nucleotides and located between protein-coding genes[1][3]. LINC01117 is highly expressed in lung adenocarcinoma (LUAD) cells and tissues and plays a significant role in promoting migration and invasion of cancer cells[2][4][6]. Mechanistically, LINC01117 regulates the epithelial–mesenchymal transition (EMT) process, largely by modulating the nuclear and cytoplasmic distribution of YAP1, a key effector of the Hippo signaling pathway[2][4][6]. Knockdown of LINC01117 suppresses EMT and reduces cell motility, while overexpression enhances pro-metastatic features. Its expression is associated with poor prognosis in lung adenocarcinoma patients, suggesting its potential utility as a prognostic biomarker and as a potential non-coding RNA therapeutic target. There are currently no known drugs that directly target LINC01117, but its functional roles make it an emerging focus for research into RNA-based cancer therapeutics.

Other names

LINC01117

Not applicable for classical small molecule or antibody targeting; functionally, LINC01117 can be silenced by RNA interference (siRNA) or modulated by overexpression systems in research contexts